Tuesday, July 4, 2023
This drug developed by AI for lungs disease enters human clinical trials
Idiopathic Pulmonary Fibrosis (IPF), a disease that causes scarring in the lungs, has a new AI-designed drug named INS018-055 that has entered human clinical trials. Insilico Medicine has developed this drug named using its generative AI platform. INS018-055 clinical trials taking place in China could offer an alternative treatment with fewer side effects. Insilico Medicine is also developing two more drugs using AI, a Covid-19 drug in Phase one trial, and a USP1 inhibitor for the treatment of solid tumours that has already received FDA approval. https://ift.tt/wUZB8DE
Subscribe to:
Post Comments (Atom)
Sources: after five Thinking Machines staff left, investors are rattled, potentially impacting fundraising; two researchers quit via Slack during an all-hands (The Information)
The Information : Sources: after five Thinking Machines staff left, investors are rattled, potentially impacting fundraising; two researc...
-
http://bit.ly/2XqNIDz
-
Amrith Ramkumar / Wall Street Journal : An interview with White House OSTP Director Michael Kratsios, a Peter Thiel protégé confirmed by ...
No comments:
Post a Comment